Cytori Cell Research Institute,Inc. Logo

Cytori Cell Research Institute,Inc.

Develops devices and cell therapies using a patient's fat tissue to repair injury and treat disease.

3750 | T

Overview

Corporate Details

ISIN(s):
JP3426500009
LEI:
Country:
Japan
Address:
千代田区麹町2丁目3番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cytori Cell Research Institute, Inc., now operating as ADR120S, Inc., is a regenerative medicine company focused on developing novel cell therapies. The company engages in the research, development, production, and sale of medical devices and related kits for cell-based treatments. Its core technology centers on a proprietary system to extract and concentrate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue. These therapies are designed to repair injured tissue, preserve function, and address various diseases with unmet medical needs, such as osteoarthritis and diabetic foot lesions. The company aims to provide safe and effective treatment options by harnessing the potential of cellular therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:04
Registration Form
確認書
Japanese 8.6 KB
2025-11-14 08:03
Interim / Quarterly Report
半期報告書-第22期(2025/04/01-2026/03/31)
Japanese 194.2 KB
2025-11-07 07:42
Registration Form
確認書
Japanese 8.3 KB
2025-11-07 07:39
Annual Report
訂正有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 597.9 KB
2025-07-01 04:31
AGM Information
臨時報告書
Japanese 24.3 KB
2025-06-27 09:17
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 09:16
Annual Report
有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 946.5 KB
2025-06-27 09:16
Governance Information
内部統制報告書-第21期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-05-30 02:01
Regulatory Filings
臨時報告書
Japanese 20.1 KB
2025-02-10 08:41
AGM Information
臨時報告書
Japanese 20.5 KB
2025-01-06 08:19
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 08:05
Interim / Quarterly Report
半期報告書-第21期(2024/04/01-2025/03/31)
Japanese 190.1 KB
2024-09-24 09:07
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-07-29 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.5 KB

Automate Your Workflow. Get a real-time feed of all Cytori Cell Research Institute,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cytori Cell Research Institute,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cytori Cell Research Institute,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xcell Therapeutics Inc. Logo
Develops serum-free media & automated systems for cell therapy & regenerative medicine.
South Korea
373110
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB

Talk to a Data Expert

Have a question? We'll get back to you promptly.